Testing and clinical implications for non‐V600
 BRAF
 mutations in metastatic
 NRAS
 
 mt
 
 melanoma

Richtig, Georg; Richtig, Erika; Kashofer, Karl; Koch, Lukas; Winter, Gerlinde; Höefler, Gerald; Pichler, Martin; Ehall, Barbara; Grübler, Martin; Heinemann, Ákos; Aigelsreiter, Ariane

doi:10.1111/bjd.15222

Cited by 3 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BRAF V600E represents 85% of BRAF V600 mutations [ 4 ]. Historically, NRAS and BRAF mutations were described as mutually exclusive [ 5 ], but the advances of genetic knowledge and the wider genetic screening are reeling us away from this old truth.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report

Croix,

Levallet,

Richard

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

“…BRAF class I mutations ( BRAF V600E / V600K or V600R ) correspond to BRAF V600 , leading to a monomer with an activity 500 fold superior to wild type BRAF [ 5 ], causing enhanced activity of the MAP Kinase pathway through a RAS – independent signal. They are responsive to BRAF inhibitors (BRAFi): vemurafenib, dabrafenib, encorafenib.…”

Section: Introductionmentioning

confidence: 99%

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report

Croix,

Levallet,

Richard

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…However, the response rate to MEK inhibitors is variable, suggesting that NRAS signaling does not solely act on the MAPK pathway [35]. In the literature, new mutations in the MAPK pathway and other pathways involved in proliferation and growth have been suggested as putative escape mechanism, but it might also be possible that there are some epigenetic modifications involved [36]. …”

Section: Introductionmentioning

confidence: 99%

Function and Clinical Implications of Long Non-Coding RNAs in Melanoma

Richtig

Ehall

Richtig

et al. 2017

IJMS

View full text Add to dashboard Cite

Metastatic melanoma is the most deadly type of skin cancer. Despite the success of immunotherapy and targeted agents, the majority of patients experience disease recurrence upon treatment and die due to their disease. Long non-coding RNAs (lncRNAs) are a new subclass of non-protein coding RNAs involved in (epigenetic) regulation of cell growth, invasion, and other important cellular functions. Consequently, recent research activities focused on the discovery of these lncRNAs in a broad spectrum of human diseases, especially cancer. Additional efforts have been undertaken to dissect the underlying molecular mechanisms employed by lncRNAs. In this review, we will summarize the growing evidence of deregulated lncRNA expression in melanoma, which is linked to tumor growth and progression. Moreover, we will highlight specific molecular pathways and modes of action for some well-studied lncRNAs and discuss their potential clinical implications.

show abstract

Beyond the BRAF ^V ^600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients

et al. 2017

Self Cite

View full text Add to dashboard Cite

BRAF gene mutations can be found in approximately 50% of melanomas, but the most common BRAF mutation leads to substitution at residue 600 of the protein, from valine to glutamic acid. BRAF occurs in up to 95% of all melanoma cases and can be successfully blocked by using a combination of BRAF- and MEK inhibitors. The wider availability of next-generation sequencing is revealing more non-V600 BRAF mutations, and the clinical implications of these mutations are widely unknown. In this review, we will discuss the biology of the MAPK pathway and the different types of BRAF mutations as well as their effect on MEK activation. Current literature will be reviewed including in vitro data, case reports and case series.

show abstract

Testing and clinical implications for non‐V600 BRAF mutations in metastatic NRAS ^mt melanoma

Cited by 3 publications

References 11 publications

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report

Function and Clinical Implications of Long Non-Coding RNAs in Melanoma

Beyond the BRAF ^V ^600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients

Contact Info

Product

Resources

About

Testing and clinical implications for non‐V600 BRAF mutations in metastatic NRAS mt melanoma

Cited by 3 publications

References 11 publications

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report

Function and Clinical Implications of Long Non-Coding RNAs in Melanoma

Beyond the BRAF V 600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients

Contact Info

Product

Resources

About

Testing and clinical implications for non‐V600 BRAF mutations in metastatic NRAS ^mt melanoma

Beyond the BRAF ^V ^600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients